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Abstract
The mu1 opioid receptor gene, OPRM1, has long been a high-priority candidate for human genetic 
studies of addiction. Because of its potential functional significance, the non-synonymous variant 
rs1799971 (A118G, Asn40Asp) in OPRM1 has been extensively studied, yet its role in addiction 
has remained unclear, with conflicting association findings. To resolve the question of what effect, 
if any, rs1799971 has on substance dependence risk, we conducted collaborative meta-analyses of 
25 datasets with over 28,000 European-ancestry subjects. We investigated non-specific risk for 
“general” substance dependence, comparing cases dependent on any substance to controls who 
were non-dependent on all assessed substances. We also examined five specific substance 
dependence diagnoses: DSM-IV alcohol, opioid, cannabis, and cocaine dependence, and nicotine 
dependence defined by the proxy of heavy/light smoking (cigarettes-per-day > 20 versus ≤ 10). 
The G allele showed a modest protective effect on general substance dependence (OR = 0.90, 95% 
C.I. [0.83–0.97], p-value = 0.0095, N = 16,908). We observed similar effects for each individual 
substance, although these were not statistically significant, likely because of reduced sample sizes. 
We conclude that rs1799971 contributes to mechanisms of addiction liability that are shared 
across different addictive substances. This project highlights the benefits of examining addictive 
behaviors collectively and the power of collaborative data sharing and meta-analyses.
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1. INTRODUCTION
The mu opioid receptors are part of a family of G protein-coupled receptors that are 
expressed in the brain and bind endogenous and exogenous opioids. The mu1 opioid 
receptor gene (OPRM1) has been one of the most studied genes in psychoactive substance 
research. It is a receptor for opioid analgesic agents and is involved in reward and analgesic 
pathways (Kreek and Koob 1998). The non-synonymous single nucleotide polymorphism 
(SNP) rs1799971 (A118G) in exon 1 of OPRM1 causes an asparagine to aspartic acid 
substitution at the fortieth amino acid residue (Asn40Asp). The G (Asp) allele is the minor 
allele across multiple human populations, with frequencies ranging from 4% in African-
American samples to ~16% in European-ancestry samples to over 40% in some Asian 
samples (http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=1799971). Multiple 
studies have examined the functional effects of this amino acid change on expression levels 
and receptor properties such as binding affinity and signaling (Befort et al. 2001; Beyer et al. 
2004; Bond et al. 1998; Deb et al. 2010; Mague and Blendy 2010; Mague et al. 2009; Ray et 
al. 2012; Wang et al. 2014; Wang et al. 2012; Zhang et al. 2005).
Because of its potential functional significance, many human genetic studies of substance 
dependence have targeted rs1799971. However, the role, if any, of rs1799971 in substance 
dependence remains unclear (Crist and Berrettini 2013; Levran et al. 2012; Mague and 
Blendy 2010). In studies of opioid dependence, results have been mixed, with the minor (G) 
allele reported to have no effect in some studies (Crowley et al. 2003; Levran et al. 2008; 
Nelson et al. 2014; Nikolov et al. 2011) and to decrease risk in others (Bond et al. 1998; Tan 
et al. 2003). Similarly, analyses of alcohol dependence have reported increased risk (Bart et 
al. 2005; Kim et al. 2004), no effect (Bergen et al. 1997; Rouvinen-Lagerstrom et al. 2013; 
Sander et al. 1998; Xuei et al. 2007), and decreased risk (Schinka et al. 2002; Town et al. 
1999) for this allele. Analyses of rs1799971 with other addictive substances also show no 
consensus (Clarke et al. 2013; Crist and Berrettini 2013; Franke et al. 2001; Gelernter et al. 
1999; Hardin et al. 2009; Munafo et al. 2013).
Literature-based meta-analyses have evaluated the association of rs1799971 with substance 
dependence (Arias et al. 2006), opioid dependence (Coller et al. 2009; Glatt et al. 2007; 
Haerian and Haerian 2013), and alcohol dependence (Chen et al. 2012a). Three of these 
meta-analyses reported no association (Arias et al. 2006; Coller et al. 2009; Glatt et al. 
2007), while among Asian samples the G allele was reported to increase risk for alcohol 
(Chen et al. 2012a) and opioid dependence (Haerian and Haerian 2013). Although these 
meta-analyses attained large samples by combining published information, they were subject 
to heterogeneity from multiple sources, including differing phenotypes, ascertainment 
schemes, and statistical analysis models across the meta-analyzed publications.
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To clarify the effect of rs1799971 on substance dependence risk, we conducted collaborative 
meta-analyses based on new analyses of multiple datasets. Our data-driven approach moves 
beyond the limitations of literature-based meta-analyses by (1) defining consistent 
phenotypes across studies, (2) performing new, uniform analyses across datasets as in our 
previous meta-analyses (Chen et al. 2012b; Hartz et al. 2012; Saccone et al. 2010), and (3) 
inviting investigators to contribute analyses from established studies with relevant 
phenotype and genotype data, irrespective of prior publication on rs1799971.
2. METHODS
2.1. Samples and Study design
Twenty-five datasets contributed a starting sample of 28,689 study participants of European 
ancestry. Invitations to participate were sent to all studies in the NIDA Genetics Consortium, 
which NIDA formed to facilitate collaboration among investigators in addiction genetics, as 
documented by the NIDA Center for Genetic Studies (https://nidagenetics.org/studies). We 
extended invitations to additional studies suggested by consortium members as likely to 
have relevant data, and to collaborators on a previous meta-analysis of smoking quantity and 
lung disease (Saccone et al. 2010). NIDA further advertised the opportunity to participate in 
this meta-analysis project with a web announcement at http://www.drugabuse.gov/
researchers/research-resources/genetics-research-resources/collaborative-opportunities-
genetics-research. Dataset inclusion criteria were: (1) rs1799971 must have been genotyped, 
and (2) at least one of these five phenotypes must have been assessed: DSM-IV defined 
alcohol, cannabis, cocaine, or opioid dependence, or categorized cigarettes per day (CPD) 
(0–10, 11–20, 21–30, and 31+ CPD).
Study participants with a history of abstinence from alcohol (never drank) were excluded 
prior to all analyses, so that included participants satisfied a minimum exposure to alcohol. 
For the main analyses, we filtered out study participants if they had no known substance 
dependence and were also under the age of 25. Thus, we included non-dependent (control) 
participants only if they were old enough to have passed through the period of highest risk, 
so as to reduce phenotypic misclassification. For each dataset, Table 1 gives demographic 
characteristics, the allele frequency of rs1799971, and key publications. Supplementary text 
S1 provides additional details for each dataset, including study recruitment, genotyping 
methods, and data quality control.
2.2. Phenotypes
We analyzed six primary dichotomous phenotypes: a “general” substance dependence 
diagnosis (lifetime dependence on any of five substances: alcohol, nicotine, cannabis, 
cocaine, and opioids), plus the corresponding five individual substance-specific lifetime 
dependence diagnoses. General substance dependence controls were required to be non-
dependent on all substances assessed in that dataset; not all studies assessed all five 
substances. For each substance, individuals who did not meet dependence criteria were 
classified as non-dependent; abuse criteria were not considered. These phenotypes allowed 
us to examine the general (nonspecific) liability to substance dependence and compare non-
specific and substance-specific associations.
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DSM-IV criteria were used to define dependent cases for alcohol, cannabis, cocaine, and 
opioids. For nicotine dependence, we defined the proxy of heavy smoking cases (CPD > 20) 
and light smoking controls (CPD ≤ 10) for current and former smokers, based on CPD when 
they were smoking; if multiple measurements were available the maximum value was used. 
Heavy versus light CPD is more commonly measured than nicotine dependence and has 
been an informative proxy for nicotine dependence in large meta-analyses (Chen et al. 
2012b; Hartz et al. 2012; Saccone et al. 2010); smokers meeting this threshold strongly 
overlap with nicotine dependent smokers. Because CPD does not account for dependence 
items such as withdrawal (Lessov et al. 2004), secondary analyses examined the effect of 
redefining general dependence using standard definitions of nicotine dependence 
(Fagerström Test for Nicotine Dependence (Heatherton et al. 1991) and DSM-IV), in the 
subset of studies for which these were available.
In addition to filtering out subjects who did not meet minimum exposure to alcohol, we also 
defined analysis variables for exposure to each of the other four substances. For cannabis, 
cocaine, and opioids, the exposure threshold was “at least one lifetime use.” For nicotine, we 
used “at least 100 cigarettes smoked lifetime,” a commonly used threshold to define 
smoking exposure in epidemiological studies.
Table 2 shows dataset-specific counts for cases, controls, and exposed controls. Individuals 
dependent on multiple substances are counted and analyzed in the corresponding multiple 
categories.
2.3. SNP for analysis
We required rs1799971 to be genotyped in each dataset. For analyses, we coded rs1799971 
as the number of copies of the G (minor) allele.
2.4. Statistical analyses and meta-analysis
We conducted six correlated discovery tests corresponding to the six primary phenotypes: 
the general substance dependence diagnosis and the five specific substance dependence 
diagnoses. To limit the number of tests, we focused on testing for a main effect of 
rs1799971 on these outcomes. All discovery analyses filtered out study participants under 
the age of 25 with no known substance dependence to ensure that controls had passed the 
typical age of dependence onset; cases are dependent and thus have had sufficient exposure 
regardless of age. Additional interpretive tests examined the robustness and consistency of 
discovery test results, and included analyses without age filtering for comparison.
To ensure uniform analyses across datasets, the coordinating site at Washington University 
developed analysis scripts in SAS® and R. Scripts were distributed to collaborating sites, 
which then analyzed their datasets locally. Results were returned to the coordinating site for 
meta-analyses. We used standard inverse-variance-weighted meta-analysis as implemented 
in the rmeta package in R (Lumley; R Development Core Team 2012). Additionally, to be 
included in the meta-analysis of a given model, each dataset was required to have at least 
five cases and five controls available. This requirement was intended to reduce noise when 
some subgroups became very small after phenotypic filtering. All samples included for 
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general dependence in fact met a higher threshold of at least 20 cases and 20 controls. We 
report fixed effect estimates together with Cochran’s Q and I2 to evaluate heterogeneity for 
each meta-analyzed model. No significant heterogeneity was observed among the studies 
analyzed (p-value for Q > 0.05, Table S1 and Tables 3 and 4). Correspondingly, Q values 
were close to the respective degrees of freedom (number of studies) and I2 values were small 
with no values greater than 26% (Supplementary Table S1).
2.5. General substance dependence analyses
Logistic regression was used to estimate the effect of rs1799971 on general substance 
dependence with covariates for sex and age. Of the 25 available datasets, 20 had at least five 
cases (dependent at least one of the five substances) and five controls (no known substance 
dependence diagnoses and exposed to alcohol) for analysis of general substance 
dependence.
Our interpretive tests examined the robustness of the general substance dependence results 
and compared them to substance-specific effects. Specifically, to assess the influence of 
each individual dataset, each of the 20 contributing datasets was, in turn, left out of the 
meta-analysis. In this leave-one-out test, observing consistency of summary odds ratios 
would suggest that it is unlikely that the overall meta-analysis result is primarily due to a 
single study. Also, we meta-analyzed only studies that had assessed all five substances to 
examine consistency of results; the general dependence controls in these studies were 
assessed for all five substances and thus more homogenous. Finally, to compare the effect of 
rs1799971 on general substance dependence liability with its effect on the constituent 
substance-specific diagnoses, we tested for association using individuals dependent on each 
specific substance as cases compared to the same controls used in the general dependence 
analysis (non-dependent on all assessed substances).
2.6. Specific substance dependence analyses
To test the association of rs1799971 with each specific dependence diagnoses while 
accounting for the remaining diagnoses, our primary analysis used ordinal logistic 
regression with additively coded rs1799971 as the dependent variable and the five 
dependence diagnoses, four exposures, sex, and age as explanatory variables. This model 
simultaneously estimates association of rs1799971 with each substance while accounting for 
co-morbidity (Grucza et al. 2008). This analysis used only the datasets that had all five 
substance dependence diagnoses and all four exposure variables because the model required 
that there be no missing variables.
To interpret and examine the robustness of these results, we evaluated traditional logistic 
regression models on the same datasets, also accounting for co-morbidity: each specific 
substance dependence was tested as the outcome, with log-additively coded rs1799971, age, 
sex, and the remaining specific substance dependence diagnoses as explanatory variables. 
Here, cases were dependent on a given substance, and controls were exposed but not 
dependent on that substance regardless of diagnoses for the remaining four substances. 
Additionally, to test equivalence of regression coefficients from ordinal regression analyses 
of individual substances, we conducted a two sample t-test assuming unequal variance.
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To examine whether substance-specific results remained consistent with a larger number of 
datasets, we used all datasets that had assessed each substance for additional interpretive 
tests, with the dependence diagnosis as outcome and additively coded rs1799971, sex, and 
age as explanatory variables.
2.7. Multiple test correction
To estimate the effective number of independent tests corresponding to the six correlated 
discovery tests, we used matSpD [http://gump.qimr.edu.au/general/daleN/matSpD/], which 
accounts for correlations among phenotypes (Cheverud 2001; Li and Ji 2005; Nyholt 2004). 
Using Pearson correlations among the five dependence diagnoses from the studies with all 
five phenotypes assessed (see Table S3), plus one additional test for general substance 
dependence, we obtained a conservative estimate of 5.1218 independent tests, corresponding 
to a Bonferroni-corrected p-value threshold of α′ = 9.76 × 10−3 for statistical significance.
3. RESULTS
3.1. The G (Asp) allele of rs1799971 shows a modest protective effect on general 
substance dependence
We observed a significant association between rs1799971 and general substance dependence 
(Figure 1). Based on 9064 cases and 7844 age-filtered controls from 20 datasets, the G allele 
showed a modest protective effect (OR = 0.90, 95% C.I. [0.83–0.97], p-value = 9.52 × 10−3, 
N = 16,908); 15 of the 20 studies showed a protective direction of the G allele. 
Heterogeneity variance was not statistically significant (Q=20.13, p-value = 0.39). A 
secondary analysis that did not require controls to be over 25 years old yielded a similar 
odds ratio (OR = 0.90, 95% C.I. (0.84–0.98), N = 17,918), but was not statistically 
significant after multiple correction in this larger sample (p-value = 1.06×10−2), consistent 
with our hypothesis that it is important for controls to be past the typical age of risk.
Leave-one-out test of robustness yielded odds ratio estimates ranging from 0.88 to 0.92, 
with none of the 20 iterations showing significant heterogeneity. This tight range of ORs 
centered on the overall odds ratio indicates that our finding was not driven by a single 
dataset. Only a few of the individual iterations showed significant association (e.g. 4 of 20 
when using α′ =9.76×10−3 as the significance threshold), likely due to the reduced sample 
size.
To reduce potential heterogeneity among the general dependence controls, we meta-
analyzed the 10 datasets that had all five substance-specific dependence diagnoses and at 
least 5 cases and 5 controls. For these 10 datasets (3947 cases and 2348 controls), the 
summary odds ratio was 0.87 (p-value = 0.01), very similar to the discovery result based on 
20 studies.
Additionally, to aid interpretation, we compared the cases for each specific substance to the 
general dependence controls. We found that the G allele of rs1799971 was consistently 
protective (odds ratio of 0.83 to 0.93) across all five substances (Table 3), consistent with 
the interpretation that this allele is a non-substance-specific protective factor.
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To further confirm robustness, we examined the effect of redefining general dependence 
using alternative definitions for nicotine dependence, namely the Fagerström Test for 
Nicotine Dependence (FTND) (case ≥ 4, control ≤ 1; 13 studies, N = 8,481) or DSM-IV 
nicotine dependence (14 studies, N = 11,711), in place of our CPD-based heavy/light 
phenotype (20 studies, N = 16,908). Analyses of these smaller samples gave similar 
protective odds ratios for general dependence, though results were not statistically 
significant: OR = 0.91, 95% C.I. (0.81–1.02) for FTND and OR = 0.94, 95% C.I. (0.85–
1.03) for DSM-IV nicotine dependence.
3.2. For each substance-specific dependence, the G allele of rs1799971 is similarly 
protective but non-significant
In our primary test of rs1799971 genotype as the dependent variable on the 9 datasets that 
had assessed all five substance dependence diagnoses and exposures, we obtained odds 
ratios that ranged from 0.89 (nicotine dependence) to 0.92 (cocaine dependence). The odds 
ratio for each specific substance showed the same protective direction as that for general 
substance dependence, though none was statistically significant in these smaller samples 
(Table 4). Also, odds ratios for specific substances did not differ significantly from each 
other (Table S2), suggesting consistency across substances.
We also examined traditional logistic regression in these 9 datasets. Each substance 
dependence diagnosis was examined as the outcome (cases dependent on that substance and 
controls required to be non-dependent but exposed to that substance), with rs1799971 as the 
predictor and the remaining diagnoses as covariates. Results were similar to those from our 
ordinal logistic model (Table 4, bottom half). Finally, analyzing all available datasets for 
these same case/control outcomes (cases dependent on each specific substance, controls 
non-dependent and exposed to that substance) also showed protective, but non-significant, 
odds ratios consistent with those seen in the datasets that assessed all dependence diagnoses 
and exposures (Supplementary Figures S1–S5).
4. DISCUSSION
This project, the first collaborative genetic meta-analysis to investigate specific and general 
liability for these substance dependence diagnoses, has demonstrated that the G allele of 
rs1799971 has a modest protective effect on general substance dependence liability (OR = 
0.90, 95% C.I. (0.83–0.97), p-value =9.52 × 10−3) in samples of European ancestry. This is 
the first meta-analysis to show that this non-synonymous variant, which has been heavily 
studied for functional effects, is significantly associated in European ancestry samples with 
liability to substance dependence. The small but significant effect size of rs1799971 
suggests that variability in previous association reports may be due in part to sampling 
variation. This collaborative meta-analysis benefited from the opportunity to define uniform 
phenotypes across studies, perform coordinated, de novo analyses to test our hypotheses, and 
include existing datasets that have not yet focused on the question of rs1799971 and 
addiction.
The protective effect of this allele on substance dependence liability appears to be non-
specific: it is not driven primarily by dependence on any particular substance. For each 
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substance-specific subset of cases compared to the general dependence controls, we 
observed a protective effect of similar size to that observed for general dependence. 
Additional substance-specific analyses similarly showed consistent protective effects of the 
G allele. These substance-specific odds ratios were not statistically significant, but this may 
have been largely due to reduced sample size and power.
These findings indicate that rs1799971 in OPRM1 may contribute to mechanisms of 
addiction liability that are shared across different addictive substances, consistent with the 
high genetic correlation between the traits, high co-morbidity, and with prior studies 
showing that both substance-specific and non-specific genetic effects on addiction liability 
can be expected (Bierut et al. 1998; Kendler et al. 2007; Merikangas et al. 1998; Swan et al. 
1997; Tsuang et al. 1998; Vanyukov et al. 2012; Vanyukov et al. 2003). Rs1799971 is now 
one of the few examples of a genetic factor that demonstrates a similar, general effect across 
multiple substances, albeit of modest magnitude. In this sense, our study is similar to a 
genome-wide association study of multiple psychiatric disorders that identified variants 
having a common, cross-disorder genetic effect on five major psychiatric diseases (Cross-
Disorder Group of the Psychiatric Genomics Consortium 2013). Both studies underscore the 
value of investigating the genetics of general liability underlying related diseases. Genetic 
studies of addiction would therefore benefit from including measures pertaining to multiple 
substances that can then be analyzed collectively. Indeed, a very recent genome-wide study 
of general substance dependence liability using four of the five substances studied here 
(alcohol, cannabis, cocaine, opioids) reported novel associations (Wetherill et al. 2015), 
further supporting the potential benefits.
Our results are compatible with negative results from prior genome-wide meta-analyses of 
cigarettes-per-day (Liu et al. 2010; The Tobacco and Genetics Consortium 2010; 
Thorgeirsson et al. 2010). Our hypothesis-driven analyses of a single SNP translate to a 
study-wide required significance threshold of 9.76×10−3. This led to statistically significant 
evidence for a modest effect (OR=0.90) of rs1799971 on general substance dependence 
liability, in N=16,908 subjects (Table 3). The three genome-wide smoking consortia tested 
OPRM1 only in each consortium separately (N=38,000, N=31,000, and N=16,000 smokers 
with cigarettes-per-day); estimated power to have detected the nicotine-specific odds ratio of 
0.93 (Table 3) in at least one of the three consortia with genome-wide significance 
(alpha=5×10−8) is only 4%. Power details are in Supplementary Text S2. Hence it is not 
surprising that these smoking consortia did not report an OPRM1 effect.
This study contributes valuable information to connect functional findings to the clinically 
important outcome of addiction in humans. Several neurobiological, functional, and 
physiological changes have been demonstrated for the rs1799971 (A118G) amino acid 
change and a corresponding mutation in a similar region of the receptor in mice (A112G) 
(Drakenberg et al. 2006; Huang et al. 2012; Mague and Blendy 2010; Palmer and de Wit 
2012; Ray et al. 2012; Wang et al. 2014). In vitro studies of the G allele have reported 
increased binding to β- endorphin (Bond et al. 1998), altered downstream signaling (Deb et 
al. 2010), and decreased mu opioid receptor expression (Zhang et al. 2005). In human brain 
imaging, the G allele is associated with striatal dopamine response to alcohol (Ramchandani 
et al. 2011) and increased mu opioid receptor binding potential (Ray et al. 2011). In mouse 
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knock-in models (A112G), the G/G knock-in has shown reduced receptor protein levels 
overall and reduced reinforcing value of morphine in female mice (Mague et al. 2009), 
reduced G-protein signaling (Wang et al. 2014), and increased peak dopamine response to 
alcohol challenge (Ramchandani et al. 2011); changes are often brain-region specific.
It is important to note that some functional and neurobiological findings have been 
interpreted as indicating that the G allele of rs1799971 should increase risk for addiction, for 
example due to its association with greater alcohol-induced reinforcement and reward 
(Ramchandani et al. 2011; Ray and Hutchison 2004; Ray and Hutchison 2007; Ray et al. 
2010). Our data-driven evidence of a modest protective effect of this allele on substance 
dependence liability is thus surprising and all the more important to integrate with functional 
findings to understand downstream contributions to human substance dependence. A 
protective effect of the G allele on addiction may be consistent with either increased or 
decreased reward/reinforcement, for example due to varying roles of positive versus 
negative reinforcement at different stages in the transition from use to dependence. 
Modeling these connections remains an open area to be worked out by neurobiological 
theories of addiction (Ray et al. 2012).
This project demonstrates the value of collaborative data sharing and meta-analysis, as the 
modest odds ratio of rs1799971 would be challenging to detect and consistently replicate in 
modestly sized candidate gene studies (Hall et al. 2013; Hart et al. 2013). Also important 
was our approach of defining consistent phenotypes across all datasets. In particular, careful 
definition of controls can help to detect associations (Nelson et al. 2013; Schinka et al. 
2002). In our case, requiring controls to be at least 25 years of age led to stronger association 
results even with the reduced the number of controls.
This study has limitations. First, as in any meta-analysis, sample heterogeneity could not be 
completely avoided. Studies had diverse ascertainment schemes, with some designed to 
recruit dependent cases for one particular substance. Some studies recruited from the general 
population while others recruited potentially more extreme cases from treatment centers. 
Hence, over- and under-representation of phenotypes were present in contributing datasets, 
and the severity of dependence, degree of co-morbid dependence, and prevalence of 
substance exposure varied. Reduced proportions of exposed controls would reduce effective 
sample size and power for a study. But overall, uniform phenotype definitions were an 
important design feature to ameliorate effects of heterogeneity. Although some bias may 
have occurred, it seems unlikely to have been systematic in either direction. Similarly, it 
seems unlikely that systematic bias would have occurred due to differences between studies 
that contributed to this meta-analysis and those that declined to participate.
Second, this project interrogated only the non-synonymous variant rs1799971. As with any 
statistical association, our finding may reflect a proxy association for which the true 
functional variant(s) remain to be recognized. Other OPRM1 variants have been associated 
with addiction and merit consideration for future study (Clarke et al. 2013; Hancock et al. 
2015; Zhang et al. 2006a). Analyses of multiple SNPs and haplotypes will also be of future 
interest: recent evidence indicates an important role in heroin addiction for the haplotype 
structure of OPRM1, with the A allele of rs1799971 showing association only in the 
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presence of the C allele of rs3778150 (Hancock et al. 2015). Importantly, (Hancock et al. 
2015) also found that the G allele of rs1799971 is protective (A allele confers risk) on that 
background, agreeing with the direction of effect observed in our meta-analysis of general 
substance dependence.
Third, further phenotypic refinement is possible. We did not consider substance abuse 
criteria, nor did we use the newer diagnostic system, DSM-5 (American Psychiatric 
Association 2013). Our threshold for exposure was a single use for all substances except 
nicotine; therefore, the genetic effect of rs1799971 detected by our analyses may involve a 
combination of effects on development of regular/repeated use and effects on dependence. 
We focused on dichotomous diagnoses for each substance. For nicotine, we examined 
heavy/light smoking as the most widely available nicotine trait in our datasets. Consistency 
of results was confirmed using DSM-IV and Fagerström Test of Nicotine Dependence 
criteria when available. Because we focused on dichotomous diagnoses that could then be 
combined into the general substance dependence diagnosis, we did not examine quantitative 
or categorical cigarettes-per-day.
Fourth, we focused on main effects of rs1799971 to limit multiple testing. Thus, we did not 
examine gene-environment interactions (e.g., sex-specific effects) or gene-gene interactions. 
We did adjust statistically for sex, which showed no evidence for a main effect on general 
substance dependence (p = 0.57). Interactions likely have roles in a complex trait such as 
addiction, and could attenuate the genetic main effect when not accounted for (e.g. when the 
effect occurs only in a specific stratum). Thus, it is possible that the modest main effect that 
we detected could translate to a stronger effect if particular genetic or environmental 
backgrounds are considered. Future work could examine interactions nominated in the 
literature (Mague et al. 2009; Miranda et al. 2013; Ray et al. 2006).
Finally, a model that explicitly partitions the association between a general factor for any 
substance dependence and substance-specific components was not fitted to these data. 
Although such a model would allow a more refined distinction between general and specific 
associations (Medland and Neale 2010; Neale et al. 2006), we chose not to apply this 
because of the complexities of running and integrating such analyses across sites.
In closing, this data-driven, collaborative meta-analysis has demonstrated a modest 
protective effect of the G allele of rs1799971 on general liability to substance dependence. 
This work highlights the benefits of jointly studying related disorders: larger samples and 
insight into factors involved in underlying shared liability. An important strength of our 
approach is that the analyses of our datasets were designed and conducted in collaboration 
with the originating investigators. Thus, we benefited from collaborators' deep knowledge of 
their own data and our combined expertise on addiction. This effort underscores the value of 
collaboratively sharing data and expertise to accelerate discoveries.
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Figure 1. 
Forest plot of general substance dependence and rs1799971 across studies that had at least 5 
cases and 5 controls. Summary odds ratio, 95% Confidence Interval, and p-values are based 
on fixed effect meta-analysis. *indicates the subset of 10 studies that had all five specific 
substance dependence diagnoses, examined in secondary analyses to confirm consistency of 
results. Estimated heterogeneity variance was Q = 20.13 with a p-value of 0.387 among all 
20 studies and Q = 6.49 with a p-value of 0.69 among the subset of 10 studies.
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Figure 2. 
Forest plot of general substance dependence and rs1799971 across studies that had at least 5 
cases and 5 controls. Summary odds ratio, 95% Confidence Interval, and p-values are based 
on fixed effect meta-analysis. *indicates the subset of 10 studies that had all five specific 
substance dependence diagnoses, examined in secondary analyses to confirm consistency of 
results. Estimated heterogeneity variance was Q = 20.13 with a p-value of 0.387 among all 
20 studies and Q = 6.49 with a p-value of 0.69 among the subset of 10 studies.
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